Retatrutide
Metabolic research; three receptor targets · From $70
Overview
Retatrutide is a 39-residue acylated peptide that acts as a triple agonist at the GIP, GLP-1 and glucagon receptors, with reported cAMP EC50 values at the human receptors of approximately 0.064 nM (GIPR), 0.78 nM (GLP-1R) and 5.8 nM (GCGR). In vitro it is used to interrogate multi-receptor incretin and glucagon receptor signalling, including lipolytic responses in differentiated human subcutaneous adipocytes, and it has been investigated in preclinical rodent models of diet-induced obesity for effects on energy expenditure and glucose handling. It is an investigational compound and is supplied for in vitro and preclinical research use only.
- Purity
- ≥ 99%
- Form
- Lyophilized powder
- Class
- Acylated peptide
- Storage
- −20 °C, desiccated, dark
Also known as LY3437943, LY-3437943, Triple G.
Research explained
The research interest
How researchers examine responses in fat cells.
What was studied
The selected paper describes tests on human-derived fat cells grown in a lab.
Evidence context
The selected source concerns human-derived cells grown in a laboratory, rather than a trial in people.
Selected-source check, not a complete clinical review. No human-use recommendation.
Structure
Specifications
Identity
- CAS number
- 2381089-83-2
- Formula
- C221H342N46O68
- Molecular weight
- 4731.3 g/mol
- Chain length
- 39 residues
Material
- Purity, RP-HPLC
- ≥ 99%
- Form
- Lyophilized powder
- Appearance
- White to off-white lyophilized powder
- Vial sizes
- 5 mg, 10 mg, 15 mg
Handling
- Solubility
- DMSO approximately 50 mg/mL with sonication; water approximately 20 mg/mL with sonication and pH adjustment to ~9 with ammonium hydroxide.
- Storage
- Lyophilized powder sealed, under nitrogen, protected from light and moisture: -20 °C for approximately 1 year, -80 °C for approximately 2 years. Reconstituted stocks: -80 °C for approximately 6 months. Avoid repeated freeze-thaw cycles.
Literature and research use
- Differentiation of human subcutaneous adipocytes and measurement of lipolytic function induced by GIP or LY3437943PMID 37178114 · 2023
- Incretin triple agonist retatrutide (LY3437943) alleviates obesity-associated cancer progressionPMID 40094000 · 2025
Citations describe published preclinical and in-vitro findings for this compound class and are not a representation about this material.
Research use only
All products listed on this site are supplied strictly as chemical reference materials for in-vitro laboratory research and are labelled For Research Use Only. They are not drugs, foods, cosmetics, or medical devices. They are not intended to diagnose, treat, cure, or prevent any condition, and are not for human or veterinary consumption or administration under any circumstances.
Research use policy ›$70
$14.00 per mg
- In stock · Certificates ›